US3920834A - Light-screening compositions and method - Google Patents
Light-screening compositions and method Download PDFInfo
- Publication number
- US3920834A US3920834A US396278A US39627873A US3920834A US 3920834 A US3920834 A US 3920834A US 396278 A US396278 A US 396278A US 39627873 A US39627873 A US 39627873A US 3920834 A US3920834 A US 3920834A
- Authority
- US
- United States
- Prior art keywords
- canthaxanthin
- apo
- mixture containing
- component
- carotenal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Definitions
- ABSTRACT Oral compositions for the treatment of erythema caused by the sun utilizing as the active ingredient canthaxanthin in combination with other carotenoids are disclosed.
- a sun screen agent as hereinafter defined can be administered internally and can be stored in sufficient amounts in the skin to bring about an effect similar to the filtering effect of conventional externally applied sun screen agents.
- the internal administration of canthaxanthin in combination with other carotenoids has the desired effect. It has been found that when canthaxanthin is administered orally in combination with other carotenoids, it, as well as the other carotenoids, will become stored in the skin and prophylactically protect against sun erythema and sunburn and reduce photosenitivity.
- canthaxanthin alone protects against sunburn, sun erythema and reduces photosensitivity, it imparts an undesirable reddish color to the skin, it can, however, be used successfully in combination with other carotenoids which are capable of being stored in the skin and which filter ultraviolet light rays in the 290-310 nm. range.
- carotenoids which are suitable for use in oral sun screen compositions in combination with canthaxanthin are B-carotene, B- apo-8'-carotenal, B-apo-8'-carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin, echinenone, citranaxanthin, torularhodin aldehyde, apo-4--,B-carotenal, C dialdehyde, lycopene, capsanthin, rhodoxanthin and astaxanthin.
- the most preferred compounds of the above group for combination with canthaxanthin in sun screen compositions according to this invention are B-carotene, ,B-apo-8'-carotenal and B-apo-8-carotenoic acid ethyl ester. Of the remaining carotenoids which are suitable, bixin, zeaxanthin and crocetin are preferred.
- compositions containing the active ingredients are administered internally in any convenient dosage 2 form, preferably in the form of capsules.
- the oral ad-. ministration forms which are suitable, e.g., capsules, can contain various amounts of active ingredients, however, a total amount of from about 5 mg. to about 50 mg. of active ingredients, are generally used.
- the oral unit dosage form contains from about 10 mg. to about 30 mg. of active ingreclients.
- the active ingredients are generally administered orally on a daily basis.
- the daily dosage amounts are usually from about 5 mg. to about 100 mg. of active ingredients administered in one or more doses throughout the day. It ispreferable to administer about 50 mg. to about 100 mg. and particularly about mg. of active ingredients daily.
- the dosages and dosage regimen described relate to adults.
- the dosage for children is generally about one-half the dosage for adults administered in a similar daily regimen.
- the active combination should preferably contain at least about 50% by weight of canthaxanthin with the upper limit restricted only by the reddish color imparted to the skin. Preferably up to about 75 canthaxanthin is used in the combination.
- the remainder of the active combination in the oral dosage form e.g., from about 25 to 50 by weight is a carotenoid or mixtures thereof as listed above.
- the oral compositions can be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances with edible pharmaceutically acceptable non-toxic inert, solid or liquid carriers and/or excipients suitable for systemic administration and conventionally used in oral dosage forms.
- edible, non-toxic pharmaceutically acceptable stabilizers such as the tocopherol compounds usually used as stabilizers in oral dosage forms or edible, non-toxic pharmaceutically acceptable salts thereof as well as ascorbic acid can be included in the compositions. All the above carriers, excipients and stabilizers are intended to include only those suitable for oral administration and all are conventional and known to the pharmaceutical compounding art.
- water-soluble signifies water-soluble preparations which contain 10% by weight of the corresponding carotenoid.
- Cunthuxanthin water-soluble 100 mg.
- B-curotene I071; watersoluhle 100 mg.
- Mannitol 60 mg.
- Canthaxanthin (10%; water-soluble) 100 mg.
- B-carotene (10%: water-soluble) 100 mg.
- DL-a-Tocopheryl acetate 20 mg.
- Ascorbic acid 40 mg.
- compositions prepared according to this example equal weights of either B-apo-8-carotenal, B-apo- 8-carotenoic acid ethyl ester or citranaxanthin can be used in the place of ,B-carotene.
- a method for the prophylactic treatment of sun erythema, sunburn and photosensiti'vity caused by ultraviolet light rays which comprises orally administering to a person in need of such treatment an oral composition comprising a. pharmaceutically acceptable carriers and excipients or mixtures thereof, and
- a carotenoid selected from the group consisting of ,B-carotene, B-apo-8'-carotenal, B-apo-8+ carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin and citranaxanthin
- component (b) is a mixture containing canthaxanthin and B-carotene.
- component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenal.
- component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenoic acid ethyl ester.
- component (b) is a mixture containing canthaxanthin and citranaxanthin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Oral compositions for the treatment of erythema caused by the sun utilizing as the active ingredient canthaxanthin in combination with other carotenoids are disclosed.
Description
United States Patent [191 Kl'ziui et a1.
[ Nov. 18, 1975 LIGHT-SCREENING COMPOSITIONS AND METHOD [75] Inventors: Heinrich Kliiui, Riehen; Wilheim Friedrich Kiir'ner, Bettingen, both of Switzerland [73] Assignee: Hoffmann-La Roche Inc., Nutley,
[22] Filed: Sept. 11, 1973 [21] Appl. No.: 396,278
Related US. Application Data [63] Continuation-in-part of Ser. No. 153,118, June 14,
1971, abandoned.
[30] Foreign Application Priority Data July 10, 1970 Switzerland 10481/70 [56] References Cited UNITED STATES PATENTS 3,252,864 5/1966 Klaui 424/331 3,252,865 5/1966 Klaui 424/331 FOREIGN PATENTS OR APPLICATIONS 2,129,653 1/1972 Germany OTHER PUBLICATIONS British Journal of Dermatology, Vol. 77, Dec. 1965, pp. 622-626.
J. of Invest. Derm, Vol. 32, Jan-June 1959, pp,
Chemical Abstracts, Vol. 65:10423b, Referring to Belg. Patent 670,243 and Vol. 63:1106g to egg yolk.
Primary Examiner-Donald B. Meyer J Attorney, Agent, or FirmSamuel L. Welt; Jon S. Saxe; Gerald S. Rosen [57] ABSTRACT Oral compositions for the treatment of erythema caused by the sun utilizing as the active ingredient canthaxanthin in combination with other carotenoids are disclosed.
5 Claims, No Drawings I LIGHT-SCREENING COMPOSITIONS AND METHOD RELATED APPLICATIONS This application is a continuation-in-part of US. patent application Ser. No. 153,118, filed June 14, 1971 now abandoned, the benefit of the priority date of which is hereby claimed.
BACKGROUND or THE INVENTION Prolonged exposure to the sun, particularly in lightskinned persons, generally leads to an initial redness of the skin which becomes brown after a period of time. This redness is generally painful and can result in the skin peeling. The damage to the skin is caused by the ultraviolet portion of sunlight in the range of about 290-310 nm. Many attempts have been made to filter ofi the damaging ultraviolet wave lengths from the skin with externally applied sun screen agents. These. sun screen agents are generally satisfactory while. they are on the skin. They are glisadvantageoussince they do not remain on the skin for a sufficiently'long time to be adequately effective and as a consequence have to be repeatedly reapplied at frequent intervals. Furthermore, many of the external sun screen agents are rather greasy and uncomfortable to the user.
There is thus a need for an effective sun screen agen which is efficacious upon prolonged use and which is facily administered.
DETAILED DESCRIPTION OF THE INVENTION It has been found according to this invention that a sun screen agent as hereinafter defined can be administered internally and can be stored in sufficient amounts in the skin to bring about an effect similar to the filtering effect of conventional externally applied sun screen agents. According to this invention, it has been found that the internal administration of canthaxanthin in combination with other carotenoids has the desired effect. It has been found that when canthaxanthin is administered orally in combination with other carotenoids, it, as well as the other carotenoids, will become stored in the skin and prophylactically protect against sun erythema and sunburn and reduce photosenitivity.
While the use of canthaxanthin alone protects against sunburn, sun erythema and reduces photosensitivity, it imparts an undesirable reddish color to the skin, it can, however, be used successfully in combination with other carotenoids which are capable of being stored in the skin and which filter ultraviolet light rays in the 290-310 nm. range. Among those carotenoids which are suitable for use in oral sun screen compositions in combination with canthaxanthin are B-carotene, B- apo-8'-carotenal, B-apo-8'-carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin, echinenone, citranaxanthin, torularhodin aldehyde, apo-4--,B-carotenal, C dialdehyde, lycopene, capsanthin, rhodoxanthin and astaxanthin.
The most preferred compounds of the above group for combination with canthaxanthin in sun screen compositions according to this invention, are B-carotene, ,B-apo-8'-carotenal and B-apo-8-carotenoic acid ethyl ester. Of the remaining carotenoids which are suitable, bixin, zeaxanthin and crocetin are preferred.
The compositions containing the active ingredients are administered internally in any convenient dosage 2 form, preferably in the form of capsules. The oral ad-. ministration forms which are suitable, e.g., capsules, can contain various amounts of active ingredients, however, a total amount of from about 5 mg. to about 50 mg. of active ingredients, are generally used.
Preferably, however, the oral unit dosage form contains from about 10 mg. to about 30 mg. of active ingreclients. The active ingredients are generally administered orally on a daily basis. The daily dosage amounts are usually from about 5 mg. to about 100 mg. of active ingredients administered in one or more doses throughout the day. It ispreferable to administer about 50 mg. to about 100 mg. and particularly about mg. of active ingredients daily. The dosages and dosage regimen described relate to adults. The dosage for children is generally about one-half the dosage for adults administered in a similar daily regimen.
In order to insure the prophylactic effect against sun erythema, sunburn and reduction of photosensitivity is effected and in order to insure that sufficient active ingredients have been stored in the tissues of the skin, it is necessary to treat the patient in the manner described continuously during the period of about 10 to 20 days before expected exposure to the sun. Tests on light skinned persons conducted according to. the method of Wucherpfennig [Strahlentherapie Vol. 40, page 201 (1931)] have shown that the prophylactic use of the sun screen compositions of this invention produce a significant protective effect against ultraviolet rays and particularly protect against and delay the formation of erythema caused by the ultraviolet rays. Finally, prophylactic administration of the compositions of this invention to persons who are in general strong risks for sunburn, such as those exposed to strong sunlight in high elevations or on lakes, indicates the treatment is successful since such persons exhibited no sun erythema or sunburn.
When the combination preparations of canthaxanthin and one or more of the carotenoids listed are used, then the active combination should preferably contain at least about 50% by weight of canthaxanthin with the upper limit restricted only by the reddish color imparted to the skin. Preferably up to about 75 canthaxanthin is used in the combination. The remainder of the active combination in the oral dosage form, e.g., from about 25 to 50 by weight is a carotenoid or mixtures thereof as listed above. The oral compositions can be made by conventional compounding procedures known in the pharmaceutical art, that is, by mixing the active substances with edible pharmaceutically acceptable non-toxic inert, solid or liquid carriers and/or excipients suitable for systemic administration and conventionally used in oral dosage forms. Additionally, edible, non-toxic pharmaceutically acceptable stabilizers such as the tocopherol compounds usually used as stabilizers in oral dosage forms or edible, non-toxic pharmaceutically acceptable salts thereof as well as ascorbic acid can be included in the compositions. All the above carriers, excipients and stabilizers are intended to include only those suitable for oral administration and all are conventional and known to the pharmaceutical compounding art.
In the following examples which illustrate the invention the expression 10%; water-soluble signifies water-soluble preparations which contain 10% by weight of the corresponding carotenoid.
EXAMPLE 1 Capsules of the following composition are manufactured in a conventional manner:
Cunthuxanthin water-soluble) 100 mg. B-curotene I071; watersoluhle) 100 mg. Mannitol 60 mg. Talcum 8 mg.
EXAMPLE 2 Capsules of the following composition are manufactured in a conventional manner:
Canthaxanthin (10%; water-soluble) 100 mg. B-carotene (10%: water-soluble) 100 mg. DL-a-Tocopheryl acetate 20 mg. Ascorbic acid 40 mg. Mannitol 90 mg. Talcum 12 mg.
In the compositions prepared according to this example, equal weights of either B-apo-8-carotenal, B-apo- 8-carotenoic acid ethyl ester or citranaxanthin can be used in the place of ,B-carotene.
We claim:
1. A method for the prophylactic treatment of sun erythema, sunburn and photosensiti'vity caused by ultraviolet light rays which comprises orally administering to a person in need of such treatment an oral composition comprising a. pharmaceutically acceptable carriers and excipients or mixtures thereof, and
b. from about 5 mg. to about 50 mg. of a mixture containing from about 50% to by weight of canthaxanthin and from about 25% to 50% by weight of a carotenoid selected from the group consisting of ,B-carotene, B-apo-8'-carotenal, B-apo-8+ carotenoic acid ethyl ester, bixin, zeaxanthin, crocetin and citranaxanthin, for a period of from about 10 to about 20 days prior to expected exposure to sunlight.
2. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and B-carotene.
3. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenal.
4. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and B-apo-8'- carotenoic acid ethyl ester.
5. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and citranaxanthin.
Claims (5)
1. A METHOD FOR THE PROPHYLACTIC TREATMENT OF SUN ERYTHEMA, SUNBURN AND PHOTOSENSITIVITY CAUSED BY ULTRAVIOLET LIGHT RAYS WHICH COMPRISES ORALLY ADMINISTERING TO A PERSON IN NEED OF SUCH TREATMENT AN ORAL COMPOSITION COMPRISING A. PHARMACEUTICALLY ACCEPTABLE CARRIERS AND EXCIPIENTS OR MIXTURES THEREOF, AND B. FROM ABOUT 5 MG. TO ABOUT 50MG. OF A MIXTURE CONTAINING FROM ABOUT 50% TO 75% BY WEIGHT OF CANTHAXANTHIN AND FROM ABOUT 25% TO 50% BY WEIGHT OF A CAROTENOID SELECTED FROM THE GROUP CONSISTING OF B-CAROTENE, B-APO-8''CAROTENAL, B-APO-8''-CAROTENIC ACID ETHYL ESTER, BIXIN, ZEAXANTHIN, CROCETIN AND CITRANAXANTHIN, FOR A PERIOD OF FROM ABOUT 10 TO ABOUT 20 DAYS PRIOR TO EXPECTED EXPOSURE TO SUNLIGHT.
2. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and Beta -carotene.
3. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and Beta -apo-8''-carotenal.
4. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and Beta -apo-8''-carotenoic acid ethyl ester.
5. The method of claim 1 wherein component (b) is a mixture containing canthaxanthin and citranaxanthin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US396278A US3920834A (en) | 1970-07-10 | 1973-09-11 | Light-screening compositions and method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1048170A CH552388A (en) | 1970-07-10 | 1970-07-10 | LIGHT PROTECTION AGENTS. |
US15311871A | 1971-06-14 | 1971-06-14 | |
US396278A US3920834A (en) | 1970-07-10 | 1973-09-11 | Light-screening compositions and method |
Publications (1)
Publication Number | Publication Date |
---|---|
US3920834A true US3920834A (en) | 1975-11-18 |
Family
ID=27176441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US396278A Expired - Lifetime US3920834A (en) | 1970-07-10 | 1973-09-11 | Light-screening compositions and method |
Country Status (1)
Country | Link |
---|---|
US (1) | US3920834A (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4108880A (en) * | 1975-11-03 | 1978-08-22 | Johnson & Johnson | Esters of retinoic acid |
US4190594A (en) * | 1975-11-03 | 1980-02-26 | Johnson & Johnson | Retinoic acid derivatives |
US4713398A (en) * | 1985-08-30 | 1987-12-15 | Microbio Resources, Inc. | Naturally-derived carotene/oil composition |
WO1991003571A1 (en) * | 1989-08-30 | 1991-03-21 | Applied Food Biotechnology, Inc. | Production of zeaxanthin and zeaxanthin-containing compositions |
US5290605A (en) * | 1989-06-29 | 1994-03-01 | Niva Shapira | Sun-exposure nutritional supporting composition |
US5510551A (en) * | 1991-04-12 | 1996-04-23 | Humanetics Corporation | Extraction of carotenoids from natural sources |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
WO1996019217A1 (en) * | 1994-12-22 | 1996-06-27 | Henkel Corporation | Pharmaceutical compositions comprising lycopene |
EP0759294A2 (en) * | 1995-06-15 | 1997-02-26 | Mutsunori Fujiwara | Hypercholesterolemia therapeutic agent |
US5712311A (en) * | 1995-06-16 | 1998-01-27 | L'oreal | Cosmetic or dermatological composition with controlled release of active principle containing a photoconvertible carotenoid |
US6262109B1 (en) | 1995-12-22 | 2001-07-17 | Henkel Corporation | Methods of preventing and/or treating high serum levels of cholesterol and/or lipids |
US6433025B1 (en) * | 2000-04-13 | 2002-08-13 | Cyanotech Corporation | Method for retarding and preventing sunburn by UV light |
US20030078304A1 (en) * | 2000-03-27 | 2003-04-24 | Tove Andersson | Method of inhibiting the expression of inflammatory cytokines and chemokines |
US20030104090A1 (en) * | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
WO2003047528A2 (en) * | 2001-12-04 | 2003-06-12 | Levy Pedro E | Supplements containing annatto extracts and carotenoids and methods for using the same |
US20030108598A1 (en) * | 2000-10-27 | 2003-06-12 | Garnett Kevin M. | Zeaxanthin formulations for human ingestion |
WO2003070260A1 (en) * | 2002-02-21 | 2003-08-28 | Societe Des Produits Nestle S.A. | A photoprotective orally administrable composition for skin |
US20040081628A1 (en) * | 2002-10-28 | 2004-04-29 | Gierhart Dennis L. | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
US6787147B1 (en) * | 1998-10-23 | 2004-09-07 | Norman Huner | Solar radiation protection composition |
US20050053559A1 (en) * | 2001-11-14 | 2005-03-10 | Morris Zelkha | Carotenoid composition and method for protecting skin |
US20050069505A1 (en) * | 2002-02-21 | 2005-03-31 | Lionel Breton | Orally administrable composition for the photoprotection of the skin |
US20050147648A1 (en) * | 2003-03-10 | 2005-07-07 | Gierhart Dennis L. | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
US20050171212A1 (en) * | 2003-11-17 | 2005-08-04 | Gierhart Dennis L. | Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders |
US20060089411A1 (en) * | 2004-08-07 | 2006-04-27 | Gierhart Dennis L | Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin |
US20070082066A1 (en) * | 2003-05-07 | 2007-04-12 | Gierhart Dennis L | Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity |
US20090104169A1 (en) * | 2002-02-21 | 2009-04-23 | Nestec S. A. | Pet food composition for skin photoprotection |
WO2010149942A1 (en) | 2009-06-25 | 2010-12-29 | Institut Biophytis | Composition for protection from the sun |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3252865A (en) * | 1962-12-17 | 1966-05-24 | Hoffmann La Roche | Stabilized fat-soluble vitamin compositions |
US3252864A (en) * | 1962-12-07 | 1966-05-24 | Hoffmann La Roche | Stable fat-soluble vitamin-containing compositions |
-
1973
- 1973-09-11 US US396278A patent/US3920834A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3252864A (en) * | 1962-12-07 | 1966-05-24 | Hoffmann La Roche | Stable fat-soluble vitamin-containing compositions |
US3252865A (en) * | 1962-12-17 | 1966-05-24 | Hoffmann La Roche | Stabilized fat-soluble vitamin compositions |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4108880A (en) * | 1975-11-03 | 1978-08-22 | Johnson & Johnson | Esters of retinoic acid |
US4190594A (en) * | 1975-11-03 | 1980-02-26 | Johnson & Johnson | Retinoic acid derivatives |
US4713398A (en) * | 1985-08-30 | 1987-12-15 | Microbio Resources, Inc. | Naturally-derived carotene/oil composition |
US5290605A (en) * | 1989-06-29 | 1994-03-01 | Niva Shapira | Sun-exposure nutritional supporting composition |
WO1991003571A1 (en) * | 1989-08-30 | 1991-03-21 | Applied Food Biotechnology, Inc. | Production of zeaxanthin and zeaxanthin-containing compositions |
US5308759A (en) * | 1989-08-30 | 1994-05-03 | Applied Food Biotechnology, Inc. | Production of zeaxanthin and zeaxanthin-containing compositions |
US5427783A (en) * | 1989-08-30 | 1995-06-27 | Applied Food Biotechnology, Inc. | Zeaxanthin-containing compositions produced by flavobacterium multivorum |
US5510551A (en) * | 1991-04-12 | 1996-04-23 | Humanetics Corporation | Extraction of carotenoids from natural sources |
US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
WO1996019217A1 (en) * | 1994-12-22 | 1996-06-27 | Henkel Corporation | Pharmaceutical compositions comprising lycopene |
US6362221B1 (en) | 1994-12-22 | 2002-03-26 | Cognis Corporation | Compositions containing natural lycopene and natural tocopherol |
EP0759294A3 (en) * | 1995-06-15 | 1999-12-01 | Mutsunori Fujiwara | Hypercholesterolemia therapeutic agent |
EP0759294A2 (en) * | 1995-06-15 | 1997-02-26 | Mutsunori Fujiwara | Hypercholesterolemia therapeutic agent |
US5712311A (en) * | 1995-06-16 | 1998-01-27 | L'oreal | Cosmetic or dermatological composition with controlled release of active principle containing a photoconvertible carotenoid |
US6262109B1 (en) | 1995-12-22 | 2001-07-17 | Henkel Corporation | Methods of preventing and/or treating high serum levels of cholesterol and/or lipids |
US6787147B1 (en) * | 1998-10-23 | 2004-09-07 | Norman Huner | Solar radiation protection composition |
US20030078304A1 (en) * | 2000-03-27 | 2003-04-24 | Tove Andersson | Method of inhibiting the expression of inflammatory cytokines and chemokines |
US7078040B2 (en) * | 2000-03-27 | 2006-07-18 | Fuji Chemical Industry Co., Ltd. | Method of inhibiting the expression of inflammatory cytokines and chemokines |
US6433025B1 (en) * | 2000-04-13 | 2002-08-13 | Cyanotech Corporation | Method for retarding and preventing sunburn by UV light |
US20030104090A1 (en) * | 2000-05-05 | 2003-06-05 | Levy Pedro E. | Supplements containing annatto extracts and carotenoids and methods for using the same |
US20030108598A1 (en) * | 2000-10-27 | 2003-06-12 | Garnett Kevin M. | Zeaxanthin formulations for human ingestion |
US7691406B2 (en) | 2000-10-27 | 2010-04-06 | ZeaVision LLC. | Zeaxanthin formulations for human ingestion |
US20050053559A1 (en) * | 2001-11-14 | 2005-03-10 | Morris Zelkha | Carotenoid composition and method for protecting skin |
US10420715B2 (en) | 2001-11-14 | 2019-09-24 | Lycored Ltd. | Carotenoid composition and method for protecting skin |
WO2003047528A2 (en) * | 2001-12-04 | 2003-06-12 | Levy Pedro E | Supplements containing annatto extracts and carotenoids and methods for using the same |
WO2003047528A3 (en) * | 2001-12-04 | 2003-12-18 | Pedro E Levy | Supplements containing annatto extracts and carotenoids and methods for using the same |
US20050106131A1 (en) * | 2002-02-21 | 2005-05-19 | Lionel Breton | Photoprotective orally administrable composition for skin |
US20070280999A1 (en) * | 2002-02-21 | 2007-12-06 | Nestec S.A. | Orally administrable composition for the photoprotection of the skin |
US10688139B2 (en) | 2002-02-21 | 2020-06-23 | Société des Produits Nestlé S.A. | Orally administrable composition for the photoprotection of the skin |
WO2003070260A1 (en) * | 2002-02-21 | 2003-08-28 | Societe Des Produits Nestle S.A. | A photoprotective orally administrable composition for skin |
US20090104169A1 (en) * | 2002-02-21 | 2009-04-23 | Nestec S. A. | Pet food composition for skin photoprotection |
US20050069505A1 (en) * | 2002-02-21 | 2005-03-31 | Lionel Breton | Orally administrable composition for the photoprotection of the skin |
US8088363B2 (en) | 2002-10-28 | 2012-01-03 | Zeavision Llc | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
US8715627B2 (en) | 2002-10-28 | 2014-05-06 | Zeavision Llc | Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin |
US20040081628A1 (en) * | 2002-10-28 | 2004-04-29 | Gierhart Dennis L. | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
US9682024B2 (en) | 2002-10-28 | 2017-06-20 | Zeavision, Llc | Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin |
US9192587B2 (en) | 2002-10-28 | 2015-11-24 | Zeavision, Llc | Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin |
US8481009B2 (en) | 2002-10-28 | 2013-07-09 | Zeavision Llc | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
US8501163B2 (en) | 2002-10-28 | 2013-08-06 | Zeavision Llc | Protection against sunburn and skin problems with topical and orally-ingested dosages of zeaxanthin |
US9980922B2 (en) | 2002-12-23 | 2018-05-29 | Zeavision Llc | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
EP1643965A2 (en) * | 2003-02-01 | 2006-04-12 | ZeaVision, L.L.C. | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
EP1643965A4 (en) * | 2003-02-01 | 2010-12-15 | Zeavision L L C | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
US10307384B2 (en) | 2003-03-10 | 2019-06-04 | Zeavision Llc | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
US20050147648A1 (en) * | 2003-03-10 | 2005-07-07 | Gierhart Dennis L. | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
US9192586B2 (en) | 2003-03-10 | 2015-11-24 | Zeavision Llc | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
US9474724B2 (en) | 2003-03-10 | 2016-10-25 | Zeavision Llc | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
US10842757B2 (en) | 2003-03-10 | 2020-11-24 | Zeavision Llc | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
US11045431B1 (en) | 2003-03-10 | 2021-06-29 | Zeavision Llc | Zeaxanthin formulations with additional ocular-active nutrients,for protecting eye health and treating eye disorders |
US11173133B2 (en) | 2003-03-10 | 2021-11-16 | Zeavision Llc | Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders |
US20070082066A1 (en) * | 2003-05-07 | 2007-04-12 | Gierhart Dennis L | Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity |
US7941211B2 (en) | 2003-11-17 | 2011-05-10 | Zeavision, Llc. | Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders |
US20050171212A1 (en) * | 2003-11-17 | 2005-08-04 | Gierhart Dennis L. | Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders |
US20060089411A1 (en) * | 2004-08-07 | 2006-04-27 | Gierhart Dennis L | Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin |
WO2010149942A1 (en) | 2009-06-25 | 2010-12-29 | Institut Biophytis | Composition for protection from the sun |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3920834A (en) | Light-screening compositions and method | |
US6433025B1 (en) | Method for retarding and preventing sunburn by UV light | |
Kumari | Vitiligo treated with topical clobetasol propionate | |
Jansen et al. | Pathogenesis and treatment of acne in childhood | |
US6573299B1 (en) | Method and compositions for treatment of the aging eye | |
US5574063A (en) | Method and compositions for topical application of ascorbic acid fatty acid esters for treatment and/or prevention of skin damage | |
EP0936897B1 (en) | Composition having tanning and sun-screening activity, and cosmetic uses thereof | |
US10420715B2 (en) | Carotenoid composition and method for protecting skin | |
AU2006305546A1 (en) | Compositions for treatment of eye diseases | |
US7186685B2 (en) | Compositions comprising gelatin-glycine and carotenoids | |
DK151850B (en) | USE OF CANTHAXANTHIN AS A LIGHT FILTER SUBSTANCE IN LIGHT PROTECTION AGENTS | |
AU2002363613A1 (en) | Carotenoid composition and method for protecting skin | |
EP1210073B1 (en) | Sunscreen agent for oral administration | |
RU2003122060A (en) | CAROTINOIDS AS ANTIHYPERTENSIVE AGENTS | |
JPS61501030A (en) | Pharmaceutical composition for the treatment or prevention of acne by topical application | |
US20050031557A1 (en) | Oral administration of beta-carotene, lycopene and lutein for human skin protection | |
GB2317111A (en) | Irradiation protection method | |
FR2749511A1 (en) | COSMETIC METHOD OF TREATMENT AND PREVENTION OF SIGNS OF AGING SKIN | |
AU2019219081B2 (en) | A tanning composition | |
AU762968B2 (en) | Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood | |
JPH0791195B2 (en) | Capsule for oral administration of active vitamin Ds | |
JPH06263647A (en) | Inhibitor against lipoperoxide | |
JPH07118137A (en) | Beautifying agent |